Advertisement

Choroidal Melanoma: Clinical Trials and What Have We Learned from Them

  • Sidharth Puri
  • Aparna RamasubramanianEmail author
Chapter

Abstract

Choroidal melanoma is the most common primary intraocular tumor but its incidence is only around 5 per million. In spite of the rarity of the tumor, well conducted clinical trials have significantly altered the management, improving the overall prognosis. This chapter highlights the key clinical trials that have brought a paradigm shift in the management of choroidal melanoma.

Keywords

Choroid melanoma Uveal melanoma Collaborative ocular melanoma study (COMS) Gene profile assay 

Notes

Acknowledgements

No financial interest associated with manuscript

  • “This work was supported in part by an unrestricted institutional grant from Research to Prevent Blindness, NY, NY.”

References

  1. 1.
    Sargent DJ, Korn EL. Decade in review—clinical trials: shifting paradigms in cancer clinical trial design. Nat Rev Clin Oncol. 2014;11:625–6.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103(5):1000–7.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology. 2005;112(9):1599–607.CrossRefGoogle Scholar
  4. 4.
    Weis E, Shah CP, Lajous M, et al. The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol. 2006;124(1):54–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279–89.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.CrossRefPubMedGoogle Scholar
  7. 7.
    Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–9.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014;24(6):525–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 1990;108:1268–73.CrossRefGoogle Scholar
  10. 10.
    Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS report no. 2. In: Franklin RM, editor. Proceedings of the symposium on retina and vitreous, New Orleans Academy of Ophthalmology. New York: Kugler Publications; 1993. p. 181–90.Google Scholar
  11. 11.
    Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the collaborative ocular melanoma study. COMS report no. 3. Control Clin Trials. 1993;14:362–91.CrossRefGoogle Scholar
  12. 12.
    Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol. 1997;115:886–93.CrossRefGoogle Scholar
  13. 13.
    Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS report no. 5. Arch Ophthalmol. 1997;115:1537–44.CrossRefGoogle Scholar
  14. 14.
    Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125:745–66.CrossRefGoogle Scholar
  15. 15.
    Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: findings from the Collaborative Ocular Melanoma Study. COMS report no. 7. Control Clin Trials. 2001;22:526–37.CrossRefGoogle Scholar
  16. 16.
    Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR. Clear cell differentiation in choroidal melanoma. COMS report no. 8. Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115:894–8.CrossRefGoogle Scholar
  17. 17.
    Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol. 1998;125:767–78.CrossRefGoogle Scholar
  18. 18.
    Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998;125:779–96.CrossRefGoogle Scholar
  19. 19.
    Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. III. Local complications and observations following enucleation. COMS Report No. 11. Am J Ophthalmol. 1998;126:362–72.CrossRefGoogle Scholar
  20. 20.
    Collaborative Ocular Melanoma Study Group, et al. J Ophthalmic Nurs Technol. 1999;18(4):143–9, Part II, 18(5):219-232Google Scholar
  21. 21.
    Collaborative Ocular Melanoma Study Group. Consistency of observations from echograms made centrally in the Collaborative Ocular Melanoma Study. COMS report no. 13. Ophthalmic Epidemiol. 2002;9:11–27.CrossRefGoogle Scholar
  22. 22.
    Collaborative Ocular Melanoma Study Group. Cause-specific mortality coding: methods in the Collaborative Ocular Melanoma Study. COMS report no. 14. Control Clin Trials. 2001;22:248–62.CrossRefGoogle Scholar
  23. 23.
    Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS report no. 15. Arch Ophthalmol. 2001;119:670–6.CrossRefGoogle Scholar
  24. 24.
    Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology. 2001;108(2):348–66.CrossRefGoogle Scholar
  25. 25.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. II. Characteristics of patients enrolled and not enrolled. COMS report no. 17. Arch Ophthalmol. 2001;119:951–65.CrossRefGoogle Scholar
  26. 26.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119:969–82.CrossRefGoogle Scholar
  27. 27.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;198:2197–206.Google Scholar
  28. 28.
    Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997. Findings from patients evaluated at Collaborative Ocular Melanoma Study centers. COMS report no. 20. Arch Ophthalmol. 2003;121:1156–62.CrossRefGoogle Scholar
  29. 29.
    Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histologic measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS report no. 21. Arch Opthalmol. 2003;121:1163–71.CrossRefGoogle Scholar
  30. 30.
    Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS report no. 22. Ophthalmology. 2004;111:996–76.Google Scholar
  31. 31.
    Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, et al. Screening for metastasis from choroidal melanoma: experience of the Collaborative Ocular Melanoma Study. Collaborative Ocular Melanoma Study report no. 23. Am J Clin Oncol. 2004;22:2438–44.CrossRefGoogle Scholar
  32. 32.
    Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. IV. Ten-year mortality findings and prognostic factors. COMS report no. 24. Am J Ophthalmol. 2004;138:936–51.CrossRefGoogle Scholar
  33. 33.
    Collaborative Ocular Melanoma Study Group. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma. COMS report no. 25. Arch Ophthalmol. 2005;123:601–4.CrossRefGoogle Scholar
  34. 34.
    Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma. Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol. 2005;123:1639–43.CrossRefGoogle Scholar
  35. 35.
    Collaborative Ocular Melanoma Study Group. Incidence of cataract and outcomes after cataract surgery in the first 5 years after 125I brachytherapy in the COMS. COMS report no. 27. Ophthalmology. 2007;114:1363.CrossRefGoogle Scholar
  36. 36.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. V. Twelve-year mortality rates and prognostic factors. COMS report no. 28. Arch Ophthalmol. 2006;124:1684–93.CrossRefGoogle Scholar
  37. 37.
    Collaborative Ocular Melanoma Study -- Quality of Life Study Group. Quality of life after iodine 125 brachytherapy versus enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study prospective study. COMS-QOLS report no. 3. Arch Ophthalmol. 2006;124:226–38.CrossRefGoogle Scholar
  38. 38.
    Mashayekhi A, Shields CL, Rishi P, et al. Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control. Ophthalmology. 2015;122(3):600–9.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Sagoo MS, Shields CL, Mashayekhi A, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. Ophthalmology. 2011;118(2):402–7.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65(3):780–7.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Bechrakis NE, Petousis V, Willerding G, et al. Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. Br J Ophthalmol. 2010;94(4):460–6.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Shah SU, Shields CL, Bianciotto CG, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–75.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Singh AD, Medina CA, Singh N, et al. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456–62.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–31. Epub 2007 Aug 27PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Walter SD, Chao DL, Feuer W, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134:734–40.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Mruthyunjaya P, Seider MI, Stinnett S, Schefler A, Ocular Oncology Study Consortium. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma. Ophthalmology. 2017;124:1532–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Gezgin G, Luk SJ, Cao J, et al. PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol. 2017;135(6):541–9.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Decatur CL, Ong E, Garg N, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Kivelä TT, Piperno-Neumann S, Desjardins L, et al. Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group. Am J Ophthalmol. 2016;168:217–26.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Triozzi PL, Singh AD. Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol. 2014;1:54–62.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Goh AY, Layton CJ. Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. Clin Exp Ophthalmol. 2016;44(6):509–19.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Buder K, Gesierich A, Gelbrich G, et al. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2013;2(5):674–86.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Kentucky Lions Eye CenterUniversity of LouisvilleLouisvilleUSA

Personalised recommendations